InvoX Pharma

invoX Pharma was incorporated in March 2021 and is a wholly owned subsidiary of Sino Biopharm, a Hong Kong listed, global top 40 pharmaceutical company with more than 24,000 employees. UK-based invoX is an expanding biopharmaceutical company focusing on R&D, Clinical Development and Business Development activities in the UK, EU and US, with a core focus on oncology and respiratory therapeutics. Our core team is made up of a multicultural international group of highly experienced individuals with life sciences and technology-centred backgrounds, all with a mutual passion and ambition for creating something different. Mission: invoX’s mission by 2026 is to be a globally recognised, fully integrated pharmaceutical company with an advancing pipeline of innovative products addressing unmet healthcare needs. Purpose：We aspire to improve people’s lives by creating access to innovative medicine. Vision: To be a leading global pharmaceutical company through delivering innovative therapies for patients. Check out our science platforms: Bispecific Antibody Platform: https://f-star.com/ Soft Mist Inhalation(SMI) Platform: https://www.softhale.com/ mRNA Delivery Platform: https://www.phiontx.co.uk/